AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

COO · NASDAQ · Medical - Instruments & Supplies

CooperCompanies (COO)

Develops contact lenses, fertility services and women’s-health medical devices.

$55.19

vs last close+1.07 (+1.98%)

In millions of USD, except per-share figures

In millions	Q4 FY23Oct 2023	Q1 FY24Jan 2024	Q2 FY24Apr 2024	Q3 FY24Jul 2024	Q4 FY24Oct 2024	Q1 FY25Jan 2025	Q2 FY25Apr 2025	Q3 FY25Jul 2025	Q4 FY25Oct 2025	Q1 FY26Jan 2026	Q2 FY26Apr 2026	Q3 FY26Jul 2026
Revenue	927	932	943	1,003	1,018	965	1,002	1,060	1,065	1,024	1,082	1,066
Cost of revenue	321	308	311	340	341	305	323	368	464	329	346	401
Gross profit	607	624	631	663	678	660	679	692	601	695	735	665
	471	471	470	471	479	478	494	516	461	482	766	443
Research & development	37	40	39	39	38	41	46	45	41	44	43	42
Selling, general & administrative	388	381	380	381	391	388	399	422	419	390	676	401
Other expenses	47	50	50	50	50	50	50	50	0	48	48	0
Operating income	136	153	162	193	198	182	185	176	140	213	−31	222
	−29	−33	−32	−29	−30	−29	−40	−24	−24	−21	−17	−21
Interest expense	26	30	29	29	27	26	33	25	24	22	21	27
Other non-operating income	3	3	3	0	3	3	16	−2	24	−2	−4	0
Income before tax	106	120	130	164	169	153	145	152	117	192	−48	202
Income tax expense	22	39	41	59	51	49	57	54	32	61	30	−231
Net income from continuing operations	85	81	89	105	118	104	88	98	85	131	−78	433
Net income	85	81	89	105	118	104	88	98	85	131	−78	433
EPS, basic	$0.43	$0.41	$0.45	$0.53	$0.59	$0.52	$0.44	$0.49	$0.43	$0.66	−$0.40	$2.24
EPS, diluted	$0.42	$0.41	$0.44	$0.52	$0.58	$0.52	$0.44	$0.49	$0.43	$0.66	−$0.40	$2.24
Weighted average shares, basic	198	198	199	199	201	201	200	201	198	197	195	193
Weighted average shares, diluted	200	200	201	201	201	201	201	201	198	197	195	193
EBITDA	225	247	257	281	287	270	261	273	215	310	68	317
Depreciation & amortization	93	97	98	89	91	91	93	95	98	96	95	95
EBIT	133	150	159	192	196	179	169	177	117	215	−28	222